附子-大黄药对治疗阳虚类疾病配伍机制研究进展

附子-大黄为典型的寒热药对,首见于《金匮要略》之大黄附子汤,二药配伍可发挥减毒增效的作用,故已广泛应用于临床。基于中药配伍理论阐释了附子-大黄药对配伍关系,通过综述近年来关于其配伍的研究,从其配伍后毒性及有效成分体外含量、体内代谢变化,药效变化和治疗阳虚类疾病的应用等方面具体阐释了附子-大黄药对减毒增效的内在配伍机制,以期为中药复方配伍规律的总结提供科学依据和参考,为临床更安全有效地应用附子-大黄药对提供理论依据。

Research progress on compatibility mechanism of drug pair of Aconiti Lateralis Radix Preparata and Rhei Radix et Rhizomain treatment of yang deficiency diseases

Fuzhi (Aconiti Lateralis Radix Preparata) and Dahuang (Rhei Radix et Rhizoma) (RALP-RRR) is a typical cold-heat drug pair, which was first found in Dahuang Fuzi Decoction of "Synopsis of the Golden Chamber". The compatibility of two drugs can play the roles of toxicity-reducing and efficacy-enhancing, so they had been widely used in clinical practice. Based on the theory of compatibility of traditional Chinese medicine, the compatibility relationship of RALP-RRR in recent years was reviewed in this paper. The internal compatibility mechanism of RALP-RRR for reducing toxicity and enhancing efficacy was interpreted specifically from the following three aspects:changes of toxic or active ingredients content in vitro and metabolism in vivoafter compatibility, pharmacodynamic changes and application in treatment of yang deficiency diseases, in order to provide scientific basis and reference for summarizing the compatibility rules of traditional Chinese medicine compound and provide theoretical basis for safer and more effective clinical application of RALP-RRR.